Ligritinib is an orally bioavailable inhibitor that reversibly binds the AXL receptor tyrosine kinase and prevents its activation. It is being studied in advanced cancer.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
AB-801
Drug type
Small molecule
Targets
AXL receptor tyrosine kinase (AXL)
Mechanism
Inhibitor of AXL receptor tyrosine kinase (AXL)
Pathways
AXL-mediated signal transduction, tumor cell growth, proliferation and migration, AXL-mediated immunosuppression
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.